We are live on
!
Find out more
SCM
Suvretta Capital Management Portfolio holdings
AUM
$3.92B
1-Year Est. Return
86.67%
This Fund
S&P 500
This Quarter
Est. Return
-0.84%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.41B
AUM Growth
-$222M
(-8.4%)
Cap. Flow
-$88.5M
Cap. Flow
% of AUM
-3.67%
Top 10 Holdings %
Top 10 Hldgs %
36.65%
Holding
102
New
13
Increased
22
Reduced
25
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$92.7M |
| 2 |
Meta Platforms (Facebook)
META
|
+$80.8M |
| 3 |
Take-Two Interactive
TTWO
|
+$66.6M |
| 4 |
Walt Disney
DIS
|
+$61.6M |
| 5 |
ServiceNow
NOW
|
+$57.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$92.5M |
| 2 |
Centene
CNC
|
+$68.3M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$63.9M |
| 4 |
Royalty Pharma
RPRX
|
+$52.8M |
| 5 |
Viatris
VTRS
|
+$40.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.67% |
| 2 | Industrials | 13.65% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Communication Services | 10.93% |
| 5 | Technology | 7.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACLX
26
DELISTED
Arcellx
ACLX
| $42.2M | 1.75% |
2,249,533
-221,026
| -9% | -$4.23M |
|
|
ITCI
27
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $39.6M | 1.65% |
851,958
-486,742
| -36% | -$25.4M |
|
|
XYZ
28
Block Inc
XYZ
$47.5B
| $36.4M | 1.51% |
661,540
-18,136
| -3% | -$1.28M |
|
29
McKesson
MCK
$101B
| $35.6M | 1.48% |
104,850
+48
| +0% | +$16.7K |
|
30
CALL
Las Vegas Sands
LVS
$29.6B
| $33.4M | 1.39% |
+890,000
| New | +$33.2M |
|
31
ProKidney
PROK
$337M
| $28.8M | 1.19% |
+3,193,175
| New | +$27.8M |
|
32
Fulcrum Therapeutics
FULC
$297M
| $28.5M | 1.19% |
3,528,000
+172,376
| +5% | +$1.23M |
|
|
KZR
33
DELISTED
Kezar Life Sciences
KZR
| $28.2M | 1.17% |
327,552
-113,678
| -26% | -$11M |
|
34
Sutro Biopharma
STRO
$421M
| $27.9M | 1.16% |
502,000
+37,500
| +8% | +$2.22M |
|
35
Cogent Biosciences
COGT
$7.24B
| $27.8M | 1.15% |
1,862,600
+1,262,600
| +210% | +$17.3M |
|
|
KDNY
36
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $27.3M | 1.13% |
1,390,000
-394,200
| -22% | -$7.91M |
|
37
Agios Pharmaceuticals
AGIO
$1.93B
| $27.1M | 1.13% |
959,214
-1,362,586
| -59% | -$36.5M |
|
38
Insmed
INSM
$28.6B
| $26.5M | 1.1% |
1,230,800
-847,880
| -41% | -$20.3M |
|
39
EyePoint Inc
EYPT
$1.2B
| $25.6M | 1.06% |
3,233,597
+265,390
| +9% | +$2.47M |
|
|
KALV
40
DELISTED
KalVista Pharmaceuticals
KALV
| $24.8M | 1.03% |
1,707,100
-221,100
| -11% | -$3.09M |
|
|
MRNS
41
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $23.5M | 0.98% |
3,537,700
+26,869
| +0.8% | +$165K |
|
42
Prothena Corp
PRTA
$459M
| $19.2M | 0.8% |
+316,531
| New | +$10M |
|
43
GFL Environmental
GFL
$14.9B
| $19.1M | 0.79% |
753,818
-149,314
| -17% | -$4.13M |
|
44
Marriott International
MAR
$92.3B
| $18.9M | 0.78% |
134,800
-157,887
| -54% | -$24.1M |
|
|
PNT
45
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $18M | 0.75% |
2,330,902
-683,506
| -23% | -$5.8M |
|
46
Heron Therapeutics
HRTX
$92.9M
| $11.8M | 0.49% |
2,807,000
-444,048
| -14% | -$1.74M |
|
47
Eli Lilly
LLY
$1.06T
| $11.4M | 0.47% |
+35,200
| New | +$11.2M |
|
48
Legend Biotech
LEGN
$4.01B
| $11.2M | 0.46% |
+274,200
| New | +$12.9M |
|
49
PepGen
PEPG
$197M
| $10.7M | 0.45% |
1,180,984
-444
| -0% | -$4.36K |
|
|
AKLI
50
DELISTED
Akili Inc
AKLI
| $8.19M | 0.34% |
+3,624,163
| New | +$26M |
|
Similar funds
MIM
BCP
AS
MSI
FLSM
LWCA
TFM
USCWA
Suvretta Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Suvretta Capital Management held 102 positions worth $2.41B, down 8.4% from $2.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Suvretta Capital Management withdrew a net $88.5M in Q3 2022, closing 29 positions and reducing 25 holdings. Its most notable exit was Humana, an estimated $92.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Suvretta Capital Management opened a new position in Amazon worth $82.9M.
- Suvretta Capital Management's largest Q3 2022 buy was Amazon: 733,460 shares worth $82.9M.
- Suvretta Capital Management added most to Walt Disney in Q3 2022, an estimated $61.6M increase.
- Suvretta Capital Management's biggest Q3 2022 reduction was Royalty Pharma, cutting an estimated $52.8M.
- Suvretta Capital Management fully exited Humana in Q3 2022, selling an estimated $92.5M.
- Suvretta Capital Management's ten largest holdings make up 37% of its $2.41B portfolio in Q3 2022.
- Suvretta Capital Management opened 13 new positions and closed 29 in Q3 2022.
- Suvretta Capital Management's portfolio value fell 8.4% quarter-over-quarter to $2.41B.
Based on Suvretta Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.